Nano-ZrO2-Catalyzed Biginelli Reaction and the Synthesis of Bioactive Dihydropyrimidinones That Targets PPAR-γ in Human Breast Cancer Cells
Authors:
- Suresha N. DeveshegowdaSDSuresha N. Deveshegowda
- Ji-Rui YangJYJi-Rui Yang
- Zhang XiZXZhang Xi
- Omantheswara NagarajaONOmantheswara Nagaraja
- Kashifa Fazl-Ur-RahmanKFKashifa Fazl-Ur-Rahman
- Bhanuprakash C. NarasimhacharBNBhanuprakash C. Narasimhachar
- Gautam SethiGautam Sethi
- Ganga PeriyasamyGPGanga Periyasamy
- Mahendra MadegowdaMMMahendra Madegowda
- Shobith RangappaSRShobith Rangappa
- Vijay PandeyVPVijay Pandey
- Peter E. LobiePLPeter E. Lobie
Open Access
Abstract
Bioactive dihydropyrimidinones (DHPs) were designed and synthesized by a multicomponent Biginelli reaction. The reaction was catalyzed by the polarized surface of nano-zirconium dioxide with partial positive charge of 0.52e at the Zr center and a negative charge of −0.23e at the oxygen center. There was good corroboration between the computed and experimental ZrO2 cell parameters and bond distances as determined by in silico and in vitro experimental methods. Since DHPs were found to target the peroxisome proliferator-activated receptor (PPAR)-γ, we tested these ligands toward MCF-7 cell toxicity, which revealed that the compounds 4d [ethyl-4-(4′-fluoro-[1,1′-biphenyl]-4-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate] and 4e [ethyl-4-(3′-methoxy-[1,1′-biphenyl]-4-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate] inhibited proliferation with IC50 values of 11.8 and 15.8 μM, respectively. Further, our bioinformatic analysis found that the active molecule 4d, fit into the enzyme’s catalytic site, almost in the same position as rosiglitazone, which was buried deep inside the cavity. In conclusion, we herein report novel DHPs which could be better structures to help explore a new class of synthetic PPAR-γ ligands.Keywords
Funding Information
- Vision Group on Science and Technology (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
- Shenzhen Key Laboratory of Innovative Oncotherapeutics (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
- Shenzhen Development and Reform Commission Subject Construction Project (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
- Overseas Research Cooperation Project (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
- Tsinghua University Stable Funding Key Project (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
- Shenzhen Bay Laboratory (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
- China and TBSI Faculty Start-up Funds, China (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
- OBC Cell, University of Mysore, Karnataka (GRD-637, ZDSYS20200820165400003, [2017]1434, HW2020008, WDZC20200821150704001, 21310031)
This publication has 65 references indexed in Scilit:
- Cucurbitane Triterpenoid fromMomordica charantiaInduces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated ReceptorγActivationEvidence-Based Complementary and Alternative Medicine, 2013
- Anti-cancer activity of novel dibenzo[b,f]azepine tethered isoxazoline derivativesBMC Chemical Biology, 2012
- Anti-Tumor Activity of a Novel HS-Mimetic-Vascular Endothelial Growth Factor Binding Small MoleculePLOS ONE, 2012
- Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial AgonistsPLOS ONE, 2012
- A Combined Ligand‐ and Structure‐Based Virtual Screening Protocol Identifies Submicromolar PPARγ Partial AgonistsChemMedChem, 2010
- Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancerWorld Journal of Biological Chemistry, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- PPAR‐γAgonists and Their Effects on IGF‐I Receptor Signaling: Implications for CancerPPAR Research, 2009
- Fat and Beyond: The Diverse Biology of PPARγAnnual Review of Biochemistry, 2008
- New cholinesterase inhibitors: synthesis and structure–activity relationship studies of 1,2‐benzisoxazole series and novel imidazolyl‐d2‐isoxazolinesJournal of Physical Organic Chemistry, 2005